As a holder of both, I'd say they are both still undervalued. I love the science - AVR has replicated a human valve with amazing results - and IMU look like they may have solved part of the puzzle to cure solid tumours, with incredible early results on low doses.
But that is the game - how do you accurately price potential - especially in a market where the big players use all the tricks at their disposal in an attempt to distort pricing in order to make their quarterly/monthly targets?
Pre-revenue stocks are probably never 'actual' fair value, whether it's FOMO to the upside or underappreciated and unloved to the downside - but that is where the opportunities are IMO, all hail the patient investor!
AVR will have it's day again! Good luck all.
AVR Price at posting:
$20.05 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)